Global Non-interventional Heart Failure Disease Registry

Stopped early

Conditions studied: Acute Heart Failure

In brief

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Key facts

Study ID

NCT02595814

Run by

Novartis Pharmaceuticals

People needed

18805

Starts

2014-07-23

Expected to finish

2018-03-31

Last updated by the study team

2018-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.

You may not qualify if…

• 1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).
• Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

Where it is running

• Novartis Investigative Site — San Francisco, California, United States
• Novartis Investigative Site — Chicago, Illinois, United States
• Novartis Investigative Site — Indianapolis, Indiana, United States
• Novartis Investigative Site — Kansas City, Kansas, United States
• Novartis Investigative Site — New Orleans, Louisiana, United States
• Novartis Investigative Site — New Orleans, Louisiana, United States
• Novartis Investigative Site — Detroit, Michigan, United States
• Novartis Investigative Site — Detroit, Michigan, United States
• Novartis Investigative Site — Jackson, Mississippi, United States
• Novartis Investigative Site — New York, New York, United States
• Novartis Investigative Site — Stony Brook, New York, United States
• Novartis Investigative Site — Cincinnati, Ohio, United States
• Novartis Investigative Site — Nashville, Tennessee, United States
• Novartis Investigative Site — Dallas, Texas, United States
• Novartis Investigative Site — Algiers, Algeria
• Novartis Investigative Site — Algiers, Algeria
• Novartis Investigative Site — Algiers, Algeria
• Novartis Investigative Site — Oran, Algeria
• Novartis Investigative Site — CABA, Buenos Aires, Argentina
• Novartis Investigative Site — CABA, Buenos Aires, Argentina
• Novartis Investigative Site — Buenos Aires, Buenos Aires F.D., Argentina
• Novartis Investigative Site — Coronel Suarez, Buenos Aires F.D., Argentina
• Novartis Investigative Site — Resistencia, Chaco Province, Argentina
• Novartis Investigative Site — Rosario, Santa Fe Province, Argentina
• Novartis Investigative Site — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.